Please login to the form below

Not currently logged in
Email:
Password:

Former AstraZeneca man Graham Walker joins Idea Pharma

Will work with product teams to bridge gap between clinical and commercial

Graham Walker - IDEA PharmaDr Graham Walker has joined product design consultants Idea Pharma as a member of its Ideation team.

He will work alongside global product teams to form strategies for compounds in phase II development in an attempt to link more closely the clinical and commercial stages of a drug's lifespan.

Dr Walker's previous experience in the field includes two years at AstraZeneca between 2009 and 2010 where he served as therapy area physician - oncology.

During his time at the pharma company he was part of the team that helped bring the non small cell lung cancer (NSCLC) drug Iressa (gefitinib) to market.

Dr Walker later left AZ to join Napp Pharmacueuticals in the UK where he worked on the company's respiratory products.

Prior to his career in the industry, Dr Walker served in the clinical environment at several UK hospitals.

He was also director of his own technology company, HealthTrade, from 2001 to 2008, which used the latest technological advancements to provide healthcare solutions.

“My career to date has been built on spearheading innovation within many commercial organisations,” said Dr Walker, “so it makes complete sense to join Idea, a company that is clearly leading the industry in ensuring innovative drugs get to market in great shape. I look forward to tackling the challenges that lie ahead.”

Mike Rea, Idea's CEO, commented: “We were really lucky to find Graham. He was about to accept a great position with one of the 'top 5' when we met.”

14th May 2012

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

Here at Cuttsy+Cuttsy, we believe in making the world a better place by bringing trusted, accessible information to all and...

Latest intelligence

Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...
Reframing rare to increase earlier diagnosis of Gaucher Disease
Sanofi Genzyme wanted to reach haematologists; the specialist physicians most likely to encounter patients with Gaucher Disease prior to diagnosis. The problem? Gaucher Disease is considered very rare and its...